阿司匹林治疗肺心病临床缓解期的疗效分析

Therapeutic Effect of Aspirin in the Treatment of Pulmonary Heart Disease during Clinical Remission

目的探讨阿司匹林对肺心病临床缓解期的治疗价值。方法采用双盲法的分组形式,对该院于2016年4月—2017年4月期间所收治的62例肺心病患者予以分组,实验组(n=31)行阿司匹林治疗,对照组(n=31)行常规治疗,对比治疗后两组的临床总有效率、WHOQOL-BREF评分等指标。结果临床总有效率分析,实验组总有效率93.6%优于对照组64.4%,两组对比差异有统计学意义(χ~2=7.883 8,P=0.004 9 <0.05);WHOQOL-BREF量表生存质量积分对比中,实验组以及对照组治疗前评分分别为(58.3±5.1)分、(57.8±2.6)分,组间对比差异无统计学意义(P>0.05);治疗后实验组(69.1±4.6)分高于对照组(64.8±3.2)分,对比差异有统计学意义(P<0.05);WHOQOL-BREF量表各维度评分分析,实验组治疗前生理维度评分(12.37±1.52)分、心理维度评分(13.52±2.79)分、社会维度评分(8.62±1.05)分、环境维度评分(23.00±1.88)分和对照组上述评分(12.35±1.51)分、(13.63±1.25)分、(8.65±1.04)分,(22.81±1.68)分对比差异无统计学意义(P>0.05);经过为期2个月的治疗后,实验组的生理、心理评分分别为(18.44±1.73)分、(17.07±2.35)分,对照组分别为(16.06±1.63)分、(15.77±1.18)分,两组差异有统计学意义(P<0.05),社会以及环境评分,实验组为(8.65±0.98)分、(23.13±1.80)分,对照组为(8.69±0.43)分、(23.08±1.67)分,组间对比差异无统计学意义(t=0.208 1,P=0.835 9;t=0.113 3,P=0.910 1,P>0.05)。结论将阿司匹林应用于肺心病治疗后,能够对患者的生存质量评分予以改善,提升生活质量,提升总有效率。

Objective To investigate the therapeutic value of aspirin in the clinical remission period of pulmonary heart disease. Methods 62 patients with pulmonary heart disease admitted to our hospital from April 2016 to April 2017 were divided into two groups. The experimental group(n=31) was treated with aspirin and the control group(n=31) routine treatment, comparing the total effective rate of the two groups after treatment, WHOQOL-BREF score and other indicators. Results The total effective rate of clinical analysis showed that the total effective rate of the experimental group was 93.6%higher than that of the control group(64.4%). The statistical significance of the two groups was(χ^2=7.883 8, P=0.004 9<0.05);WHOQOL-BREF scale quality of life score, the pre-treatment scores of the experimental group and the control group were(58.3±5.1) points and(57.8±2.6) points respectively. There was no difference between the groups(P>0.05). After treatment, the experimental group(69.1±4.6) points. Compared with the control group(64.8±3.2)points, the difference was statistically significant(P<0.05);the WHOQOL-BREF scale was scored in each dimension, and the experimental group had a pre-treatment physiological dimension score(12.37±1.52)points and a psychological dimension score(13.52±2.79)points,social dimension score(8.62±1.05)points, environmental dimension score(23.00±1.88)points and control group(12.35±1.51)points,(13.63±1.25)points,(8.65±1.04)points,(22.81±1.68)points. There was no statistically significant difference in the comparison(P>0.05);after 2 months of treatment, the physiological and psychological scores of the experimental group were(18.44±1.73)points and(17.07±2.35)points, respectively, and the control group was(16.06 ±1.63)points,(15.77±1.18)points,the two groups have statistical significance difference(P<0.05), social and environmental scores, the experimental group was(8.65±0.98) points,(23.13±1.80) points, and the control group was(8.69±0.43) points,(23.08±1.67) points, the comparison between groups did not exist(t=0.208 1,P=0.835 9;t=0.113 3,P=0.910 1,P>0.05). Conclusion After applying aspirin to pulmonary heart disease, it can improve the patient’s quality of life score, improve the quality of life and improve the total efficiency.